沙库巴曲缬沙坦钠片联合美托洛尔缓释片治疗慢性心力衰竭的效果分析

Effect of sacubitril valsartan sodium tablets combined with metoprolol sustained-release tablets on chronic heart failure

目的分析沙库巴曲缬沙坦钠片联合美托洛尔缓释片治疗慢性心力衰竭(CHF)的效果。方法抽取2020年4月至2022年3月濮阳市人民医院收治的CHF患者132例,采用随机数字表法分为研究组和对照组,每组66例。对照组使用美托洛尔缓释片治疗,研究组在对照组基础上使用沙库巴曲缬沙坦钠片治疗。比较两组疗效、不良反应发生率及治疗前后心功能指标[左心室短轴缩短率(FS)、左室射血分数(LVEF)、左室收缩末直径(LVDs)]、血清因子[N端B型利钠肽原(NT-proBNP)、C反应蛋白(CRP)]水平、明尼苏达心力衰竭生活质量问卷表(MLHFQ)评分。结果研究组总有效率(96.97%,64/66)较对照组(75.76%,50/66)高(P<0.05);治疗后与对照组比较,研究组FS、LVEF水平较高,LVDs水平较低(P<0.05),NT-proBNP、CRP水平较低(P<0.05),MLHFQ评分较低(P<0.05)。研究组不良反应发生率(6.06%,4/66)与对照组(10.61%,7/66)比较差异未见统计学意义(P>0.05)。结论沙库巴曲缬沙坦钠片联合美托洛尔缓释片治疗CHF可缓解机体炎症,改善患者心功能,提升生活质量,且二者联合治疗效果较好,用药安全性高。

Objective To analyze the effect of sacubitril valsartan sodium tablets combined with metoprolol sustained-release tablets in the treatment of chronic heart failure(CHF).Methods A total of 132 patients with CHF treated in Puyang People’s Hospital from April 2020 to March 2022 were selected,and the patients were divided into the study group and the control group by random number table method,with 66 cases in each group.The control group was treated with metoprolol sustained-release tablets.The study group was treated with sacubitril valsartan sodium tablets based on the treatment of the control group.The efficacy,incidence of adverse reactions,cardiac function indexes including left ventricular fractional shortening(FS),left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVDs),serum factors including N-terminal pro-B-type natriuretic peptide(NT-proBNP)and C-reactive protein(CRP),and Minnesota heart failure quality of life questionnaire(MLHFQ)scores before and after treatment were compared between the two groups.Results The total effective rate of the study group was 96.97%(64/66),which was higher than that of the control group(75.76%,50/66),P<0.05.Compared with the control group,the levels of FS and LVEF in the study group were higher,and the level of LVDs was lower after treatment(P<0.05),the levels of NT-proBNP and CRP in the study group were lower(P<0.05),the MLHFQ score of the study group was lower than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group(6.06%,4/66)and the control group(10.61%,7/66),P>0.05.Conclusions Sacubitril valsartan sodium tablets combined with metoprolol sustained-release tablets in the treatment of CHF can alleviate body inflammation,improve cardiac function and quality of life.And combination of them has significant therapeutic effects and good safety.